Literature DB >> 26296498

Effective cutaneous vaccination using an inactivated chikungunya virus vaccine delivered by Foroderm.

Penny A Rudd1, Anthony P Raphael2, Miko Yamada2, Kaitlin L Nufer2, Joy Gardner1, Thuy T T Le1, Natalie A Prow3, Nhung Dang2, Wayne A Schroder1, Tarl W Prow4, Andreas Suhrbier3.   

Abstract

Foroderm is a new cutaneous delivery technology that uses high-aspect ratio, cylindrical silica microparticles, that are massaged into the skin using a 3D-printed microtextured applicator, in order to deliver payloads across the epidermis. Herein we show that this technology is effective for delivery of a non-adjuvanted, inactivated, whole-virus chikungunya virus vaccine in mice, with minimal post-vaccination skin reactions. A single topical Foroderm-based vaccination induced T cell, Th1 cytokine and antibody responses, which provided complete protection against viraemia and disease after challenge with chikungunya virus. Foroderm vaccination was shown to deliver fluorescent, virus-sized beads across the epidermis, with beads subsequently detected in draining lymph nodes. Foroderm vaccination also stimulated the egress of MHC II(+) antigen presenting cells from the skin. Foroderm thus has potential as a simple, cheap, effective, generic, needle-free technology for topical delivery of vaccines.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chikungunya virus; Cutaneous vaccination; Foroderm; Vaccine delivery

Mesh:

Substances:

Year:  2015        PMID: 26296498     DOI: 10.1016/j.vaccine.2015.07.099

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  Are there differences in immune responses following delivery of vaccines through acutely or chronically sun-exposed compared with sun-unexposed skin?

Authors:  Prue H Hart; Mary Norval
Journal:  Immunology       Date:  2019-11-06       Impact factor: 7.397

2.  Global emergence of Alphaviruses that cause arthritis in humans.

Authors:  Olivia Wesula Lwande; Vincent Obanda; Göran Bucht; Gladys Mosomtai; Viola Otieno; Clas Ahlm; Magnus Evander
Journal:  Infect Ecol Epidemiol       Date:  2015-12-18

Review 3.  Recent Progress in Vaccine Development Against Chikungunya Virus.

Authors:  Shan Gao; Siqi Song; Leiliang Zhang
Journal:  Front Microbiol       Date:  2019-12-19       Impact factor: 5.640

Review 4.  Cellular and Molecular Immune Response to Chikungunya Virus Infection.

Authors:  Ithallo S B Tanabe; Eloiza L L Tanabe; Elane C Santos; Wanessa V Martins; Isadora M T C Araújo; Maria C A Cavalcante; Ana R V Lima; Niels O S Câmara; Leticia Anderson; Dinar Yunusov; Ênio J Bassi
Journal:  Front Cell Infect Microbiol       Date:  2018-10-10       Impact factor: 5.293

5.  Using elongated microparticles to enhance tailorable nanoemulsion delivery in excised human skin and volunteers.

Authors:  Miko Yamada; Hossam Tayeb; Hequn Wang; Nhung Dang; Yousuf H Mohammed; Sam Osseiran; Paul J Belt; Michael S Roberts; Conor L Evans; Frank Sainsbury; Tarl W Prow
Journal:  J Control Release       Date:  2018-09-15       Impact factor: 9.776

6.  Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.

Authors:  Eranga Abeyratne; Kothila Tharmarajah; Joseph R Freitas; Helen Mostafavi; Suresh Mahalingam; Ali Zaid; Mehfuz Zaman; Adam Taylor
Journal:  Front Immunol       Date:  2020-03-05       Impact factor: 7.561

Review 7.  Chikungunya: bending over the Americas and the rest of the world.

Authors:  Miguel Madariaga; Eduardo Ticona; Cristhian Resurrecion
Journal:  Braz J Infect Dis       Date:  2015-12-17       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.